Pfizer (PFE) is focusing on earlier stage science for deals

Pfizer's pivot towards earlier stage science signals a strategic shift that could enhance its pipeline and innovation potential. This move may indicate confidence in future growth areas and could lead to value-accretive partnerships, potentially impacting sentiment in both the biotech sector and broader market. Investors will want to assess the implications for Pfizer's long-term strategy and how it positions them against competitors in pharmaceuticals.